CCA
ALLO icon

Cygnus Capital Advisors’s Allogene Therapeutics ALLO Stock Holding History

Cygnus Capital Advisors’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-3,234
Closed -$8K – 75
2026
Q1 		$8K Hold
3,234
– – 0.01% 97
2025
Q4 		$4K Buy
+3,234
New +$4.27K ﹤0.01% 145

Other funds holding ALLO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Cygnus Capital Advisors's ALLO Position: Q2 2026 in Review

Cygnus Capital Advisors sold out of Allogene Therapeutics (ALLO) in Q2 2026, closing a stake of 3,234 shares — an estimated $8K sold.

Cygnus Capital Advisors first reported a position in ALLO in Q4 2025 and held it in 2 quarters. The position peaked at $8K in Q1 2026. 209 funds tracked by Wall St. Rank hold ALLO as of Q2 2026.

  • Cygnus Capital Advisors reported no remaining Allogene Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Cygnus Capital Advisors sold 3,234 Allogene Therapeutics shares in Q2 2026, an estimated $8K.
  • Cygnus Capital Advisors first reported a position in Allogene Therapeutics in Q4 2025 and held it in 2 quarters.
  • Cygnus Capital Advisors's Allogene Therapeutics position peaked at $8K in Q1 2026.
  • 209 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2026.

Based on Cygnus Capital Advisors's 13F filing for Q2 2026, filed 3 Sep 2026.